Eyam Health and MMV to work on low-cost malaria prevention

Canadian biotech Eyam Health has entered a research alliance with Swiss-based nonprofit Medicines for Malaria Venture to explore monoclonal antibody-based therapies aimed at preventing malaria.

The goal is to cut both cost and complexity by using Eyam’s next-generation delivery platform and AI-enabled biologics engine to develop durable, single-shot treatments.

The collaboration centers on Gemini, a delivery system that can carry multiple antibodies in one injection, eliminating the need for cold storage and expensive lipid nanoparticles. A long-acting shot priced under $1 could offer seasonal protection to more than 50 million children and pregnant women. That would simplify current seasonal malaria chemoprevention campaigns and help reach more people.